Innovent Biologics, Inc. (1801.HK) — Upcoming Catalysts

FDA PDUFA dates, advisory-committee meetings, and Phase 2/3 readout windows for Innovent Biologics, Inc., built from public data lanes (ClinicalTrials.gov and official sources). Each row links to its source.

For informational purposes only — not investment advice. Track 1801.HK live on Mooboard →

This week4

  • Sep 24, 2026
    Innovent Biologics, Inc.(1801.HK)Phase 2/3 readout
    IBI362 · Phase 2 · Obesity; Heart Failure With Preserved Ejection Fraction (HFPEF)
    NCT06862908: A Study of IBI362 in Subjects With HFpEF or HFmrEF Combined With Obesity. Primary completion 2026-09-24 (estimated); status ACTIVE_NOT_RECRUITING.
    ClinicalTrials.gov ↗
  • Sep 30, 2026
    Innovent Biologics, Inc.(1801.HK)Phase 2/3 readout
    Pemetrexed · Phase 3 · Non-Small Cell Lung Cancer
    NCT05116462: Neoadjuvant and Adjuvant Therapy Studies of Sindilizumab in Resectable Lung Cancer. Primary completion 2026-09-30 (estimated); status ACTIVE_NOT_RECRUITING.
    ClinicalTrials.gov ↗
  • Sep 30, 2026
    Innovent Biologics, Inc.(1801.HK)Phase 2/3 readout
    IBI363+IBI305 · Phase 2 · EGFR Mutant NSCLC and Platinum Resistant Ovarian Cancer
    NCT07124793: A Study of IBI363 Combination Therapy in Participants With Advanced Solid Tumors. Primary completion 2026-09-30 (estimated); status NOT_YET_RECRUITING.
    ClinicalTrials.gov ↗
  • Sep 30, 2026
    Innovent Biologics, Inc.(1801.HK)Phase 2/3 readout
    Tirzepatide · Phase 1 / Phase 2 · Obesity
    NCT07000955: Tolerance and Pharmacokinetic/Pharmacokinetic Study of IBI362 15mg in Patients With Moderate to Severe Obesity. Primary completion 2026-09-30 (estimated); status ACTIVE_NOT_RECRUITING.
    ClinicalTrials.gov ↗

31–90 days2

  • Oct 31, 2026
    Innovent Biologics, Inc.(1801.HK)Phase 2/3 readout
    IBI3003 · Phase 1 / Phase 2 · Multiple Myeloma
    NCT06083207: A Study of IBI3003 in Subjects With Relapsed or Refractory Multiple Myeloma. Primary completion 2026-10-31 (estimated); status RECRUITING.
    ClinicalTrials.gov ↗
  • Nov 30, 2026
    Innovent Biologics, Inc.(1801.HK)Phase 2/3 readout
    Pemetrexed · Phase 2 · Resectable Stage IB-III Non-Squamous Non-Small Cell Lung Cancer
    NCT07122687: IBI363 Combined With Chemotherapy or Pembrolizumab Combined With Chemotherapy as Neoadjuvant Therapy in Resectable Stage IB-III Non-Squamous Non-Small Cell Lung Cancer. Primary completion 2026-11-30 (estimated); status RECRUITING.
    ClinicalTrials.gov ↗

Later19

  • Dec 30, 2026
    Innovent Biologics, Inc.(1801.HK)Phase 2/3 readout
    Irinotecan OR Paclitaxel or Trifluridine/tipiracil（ FTD/TPI） · Phase 3 · Unresectable or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma
    NCT06238843: A Multicenter, Phase 3 Study of IBI343 Monotherapy Versus Treatment of Investigator's Choice in Subjects With Previously Treated, Claudin (CLDN) 18.2-positive, HER2-negative, Gastric or Gastroesophageal Junction Adenocarcinoma (G-HOPE-001). Primary completion 2026-12-30 (estimated); status ACTIVE_NOT_RECRUITING.
    ClinicalTrials.gov ↗
  • Dec 31, 2026
    Innovent Biologics, Inc.(1801.HK)Phase 2/3 readout
    Dexamethasone · Phase 2 · Multiple Myeloma
    NCT07764861: A Open-Label Phase in Participants With Multiple Myeloma. Primary completion 2026-12-31 (estimated); status NOT_YET_RECRUITING.
    ClinicalTrials.gov ↗
  • Dec 31, 2026
    Innovent Biologics, Inc.(1801.HK)Phase 2/3 readout
    IBI363 · Phase 2 · Resectable Stage II-III Non-small Cell Lung Cancer
    NCT07402070: IBI363 as Neoadjuvant Therapy in Resectable Stage II-III Non-Small Cell Lung Cancer. Primary completion 2026-12-31 (estimated); status NOT_YET_RECRUITING.
    ClinicalTrials.gov ↗
  • Dec 31, 2026
    Innovent Biologics, Inc.(1801.HK)Phase 2/3 readout
    IBI362 · Phase 3 · Overweight; Metabolic Dysfunction-associated Fatty Liver Disease (MAFLD)
    NCT06884293: A Study Comparing IBI362 vs Semaglutide in Chinese Overweight or Obese Adults With Metabolic Dysfunction-associated Fatty Liver Disease （MAFLD）. Primary completion 2026-12-31 (estimated); status ACTIVE_NOT_RECRUITING.
    ClinicalTrials.gov ↗
  • Dec 31, 2026
    Innovent Biologics, Inc.(1801.HK)Phase 2/3 readout
    IBI311 · Phase 3 · Thyroid Eye Disease
    NCT07113262: A Clinical Study to Evaluate the Efficacy and Safety of IBI311 in Subjects With Inactive Thyroid Eye Disease. Primary completion 2026-12-31 (estimated); status RECRUITING.
    ClinicalTrials.gov ↗
  • Dec 31, 2026
    Innovent Biologics, Inc.(1801.HK)Phase 2/3 readout
    IBI302 · Phase 2 · Diabetic Macular Oedema
    NCT06908876: A Study to Evaluate the Efficacy and Safety of IBI302 inSubjects With Diabetic Macular Edema（DME）. Primary completion 2026-12-31 (estimated); status ACTIVE_NOT_RECRUITING.
    ClinicalTrials.gov ↗
  • Feb 28, 2027
    Innovent Biologics, Inc.(1801.HK)Phase 2/3 readout
    Aflibercept Ophthalmic · Phase 3 · Neovascular Age-related Macular Degeneration
    NCT05972473: A Study to Evaluate the Efficacy and Safety of IBI302 in Subjects With nAMD. Primary completion 2027-02-28 (estimated); status ACTIVE_NOT_RECRUITING.
    ClinicalTrials.gov ↗
  • Mar 23, 2027
    Innovent Biologics, Inc.(1801.HK)Phase 2/3 readout
    IBI3002 · Phase 2 · Atopic Dermatitis
    NCT07399067: A Proof-of-Concept Study of IBI3002 in Patients With Moderate to Severe Atopic Dermatitis. Primary completion 2027-03-23 (estimated); status RECRUITING.
    ClinicalTrials.gov ↗
  • Apr 30, 2027
    Innovent Biologics, Inc.(1801.HK)Phase 2/3 readout
    Febuxostat · Phase 3 · Gout
    NCT07414394: Tigulixostat (IBI128) vs Febuxostat in Gout. Primary completion 2027-04-30 (estimated); status ACTIVE_NOT_RECRUITING.
    ClinicalTrials.gov ↗
  • May 7, 2027
    Innovent Biologics, Inc.(1801.HK)Phase 2/3 readout
    IBI362 · Phase 3 · Sleep Apnea; Obstructive
    NCT06931028: A Study of IBI362 in Chinese Subjects With Obstructive Sleep Apnea and BMI≥28 kg/m2. Primary completion 2027-05-07 (estimated); status RECRUITING.
    ClinicalTrials.gov ↗
  • Jun 30, 2027
    Innovent Biologics, Inc.(1801.HK)Phase 2/3 readout
    IBI343 · Phase 3 · Pancreatic Cancer
    NCT07066098: A Multicenter Study of IBI343 Monotherapy Versus Placebo in Subjects With Previously Treated, Claudin (CLDN) 18.2-positive, Pancreatic Cancer(G-HOPE-002). Primary completion 2027-06-30 (estimated); status RECRUITING.
    ClinicalTrials.gov ↗
  • Jun 30, 2027
    Innovent Biologics, Inc.(1801.HK)Phase 2/3 readout
    Dupilumab · Phase 2 · Atopic Dermatitis
    NCT07330934: A Study to Evaluate Efficacy and Safety of IBI356 in Participants With Moderate to Severe Atopic Dermatitis. Primary completion 2027-06-30 (estimated); status RECRUITING.
    ClinicalTrials.gov ↗
  • Jun 30, 2027
    Innovent Biologics, Inc.(1801.HK)Phase 2/3 readout
    IBI3005 · Phase 1 / Phase 2 · Solid Tumor
    NCT07612137: Study of IBI3005 Combination Therapy in Participants With Unresectable, Locally Advanced or Metastatic Solid Tumors. Primary completion 2027-06-30 (estimated); status NOT_YET_RECRUITING.
    ClinicalTrials.gov ↗
  • Oct 31, 2027
    Innovent Biologics, Inc.(1801.HK)Phase 2/3 readout
    Placebo · Phase 3 · Adolescents With Obesity or Overweight With Weight-Related Comorbidities
    NCT07255209: A Study of IBI362 in Chinese Adolescents With Obesity or Overweight. Primary completion 2027-10-31 (estimated); status RECRUITING.
    ClinicalTrials.gov ↗
  • Nov 1, 2027
    Innovent Biologics, Inc.(1801.HK)Phase 2/3 readout
    Part A - Placebo for IBI355 · Phase 2 · Sjögren's Disease
    NCT07836660: A Study of IBI355 in Participants With Moderate-to-Severe Sjögren's Disease. Primary completion 2027-11-01 (estimated); status NOT_YET_RECRUITING.
    ClinicalTrials.gov ↗
  • Dec 28, 2027
    Innovent Biologics, Inc.(1801.HK)Phase 2/3 readout
    IBI354 · Phase 3 · Ovarian; Primary Peritoneal
    NCT06834672: Study of IBI354 Versus Investigator's Choice of Chemotherapy in Patients With Platinum-resistant Ovarian, Primary Peritoneal, or Fallopian Tube Cancer. Primary completion 2027-12-28 (estimated); status ACTIVE_NOT_RECRUITING.
    ClinicalTrials.gov ↗
  • Mar 31, 2028
    Innovent Biologics, Inc.(1801.HK)Phase 2/3 readout
    IBI343,Gemcitabine, Albumin-bound Paclitaxel · Phase 2 · CLDN18.2 Positive; Gastric/Gastroesophageal Junction Adenocarcinoma
    NCT07483554: IBI343 in Combination Therapy for Advanced Malignant Solid Tumors. Primary completion 2028-03-31 (estimated); status RECRUITING.
    ClinicalTrials.gov ↗
  • Apr 15, 2028
    Innovent Biologics, Inc.(1801.HK)Phase 2/3 readout
    Sintilimab · Phase 3 · MSI-H
    NCT05890742: A Clinical Trial Evaluating the Efficacy and Safety of IBI310 in Combination With Sintilimab, for Neoadjuvant Treatment of MSI-H/dMMR Resectable Colon Cancer. Primary completion 2028-04-15 (estimated); status ACTIVE_NOT_RECRUITING.
    ClinicalTrials.gov ↗
  • Jul 1, 2028
    Innovent Biologics, Inc.(1801.HK)Phase 2/3 readout
    Dupilumab Injection · Phase 3 · Atopic Dermatitis
    NCT07754786: A Study to Evaluate the Equivalence of IBI3027 and Dupilumab Injection in Participants With Moderate to Severe Atopic Dermatitis. Primary completion 2028-07-01 (estimated); status NOT_YET_RECRUITING.
    ClinicalTrials.gov ↗

How Innovent Biologics, Inc. has moved — past-year price reactions

How binary is 1801.HK? Its typical daily move, how often it swings ±10%, and its biggest single-day moves over the last year — useful context for sizing around a catalyst.

1.7%
typical day (1Y)
1
±10% days
47.9%
annualized vol
245
trading days
Largest single-day moves
  • +11.4%2026-05-29no matched headline
  • +9.7%2026-08-26no matched headline
  • -9.2%2025-10-09no matched headline
  • +7.8%2025-10-31no matched headline
  • +7.8%2026-07-15no matched headline
  • +7.7%2026-03-27no matched headline

Real daily price moves over the past year — not every move is a catalyst, and headlines (where shown) are a possible same-day driver, not confirmed causation.

Innovent Biologics, Inc. — active clinical pipeline

Innovent Biologics, Inc.'s registered Phase 1–3 programs by asset and indication, derived from ClinicalTrials.gov.

46 assets60 programsPh1 22Ph2 22Ph3 15· 1 post-marketing (Ph4)
AreasOncologyAutoimmuneImmunologyMetabolicCardiovascularOphthalmologyOther
IBI362Metabolic
Phase 2
Metabolic Dysfunction-associated Steatohepatitis (MASH)Obesity
Phase 3
Adolescents With Obesity or Overweight With Weight-Related ComorbiditiesOverweight (2)Sleep Apnea
IBI343Oncology
Phase 1
Locally Advanced Unresectable or Metastatic Solid Tumors
Phase 3
Pancreatic Cancer
IBI354Oncology
Phase 2
Locally Advanced Unresectable or Metastatic Solid Tumors
Phase 3
Ovarian
PemetrexedOncology · DHFR/GART/TYMS
Phase 2
Resectable Stage IB-III Non-Squamous Non-Small Cell Lung Cancer
Phase 3
Non-Small Cell Lung Cancer
SintilimabOncology · PD-1
Phase 2
Diffuse Large B-Cell Lymphoma
Phase 3
MSI-H
Aflibercept OphthalmicOphthalmology
Phase 3
Neovascular Age-related Macular Degeneration
Dupilumab InjectionImmunology
Phase 3
Atopic Dermatitis
FebuxostatOther · XDH
Phase 3
Gout
IBI306Metabolic · PCSK9
Phase 3
Non-Familial Hypercholesterolemia and Mixed Hyperlipidemia
IBI311Other
Phase 3
Thyroid Eye Disease
IBI363 + bevacizumabOncology
Phase 3
Colorectal Cancer
Irinotecan OR Paclitaxel or Trifluridine/tipiracil（ FTD/TPI）Oncology
Phase 3
Unresectable or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma
Pomalidomide CapsulesOncology
Phase 3
Relapsed or Refractory Multiple Myeloma
IBI363Oncology
Phase 1
Solid Malignancies or LymphomasSolid Tumors or Lymphoma
Phase 2
Melanoma (3)Resectable Stage II-III Non-small Cell Lung Cancer
IBI3005Oncology
Phase 1
Unresectable
Phase 2
Solid Tumor
IBI3016Cardiovascular
Phase 1
Hypertension
Phase 2
Hypertension
DexamethasoneOncology · NR3C1
Phase 2
Multiple Myeloma
DupilumabImmunology · IL-4Rα
Phase 2
Atopic Dermatitis
IBI130Oncology
Phase 2
Solid Tumor
IBI3002Immunology
Phase 2
Atopic Dermatitis
IBI3003Oncology
Phase 2
Multiple Myeloma
IBI3014Oncology
Phase 2
Unresectable Locally Advanced or Metastatic Solid Tumors
IBI302Ophthalmology
Phase 2
Diabetic Macular Oedema
IBI302 8mg doseOphthalmology
Phase 2
Neovascular Age-related Macular Degeneration
IBI343,Gemcitabine, Albumin-bound PaclitaxelOther
Phase 2
CLDN18.2 Positive
IBI343,sintilimab,oxaliplatin,S-1Other
Phase 2
CLDN18.2 Positive
IBI363+IBI305Oncology
Phase 2
EGFR Mutant NSCLC and Platinum Resistant Ovarian Cancer
Part B -TelitaciceptAutoimmune
Phase 2
Sjögren's Disease
TirzepatideMetabolic · GIP/GLP-1
Phase 2
Obesity
IBI3033Immunology
Phase 1
Atopic DermatitisImmunology (2)
Baricitinib tabletsAutoimmune
Phase 1
Active Non-segmental Vitiligo
IBI115Oncology
Phase 1
Small Cell Lung Cancer (SCLC)
IBI3001Oncology
Phase 1
Locally Advanced Solid Tumor
IBI3009Oncology
Phase 1
Small Cell Lung Cancer
IBI3011Other
Phase 1
Acute Gout Flare
IBI3026Oncology
Phase 1
Solid Tumor
IBI3027Other
Phase 1
Healthy volunteers
IBI3031Other
Phase 1
Thyroid Eye Disease
IBI3032Metabolic
Phase 1
Overweight or Obesity
IBI3035Other
Phase 1
Healthy volunteers
IBI3046Metabolic
Phase 1
Obesity and Overweight
IBI351Oncology
Phase 1
Advanced Non-Small Cell Lung Cancer
IBI363 + chemotherapyOncology
Phase 1
Advanced Malignancies
OrforglipronMetabolic
Phase 1
Overweight
SAD: subcutaneous injection in the abdomenMetabolic
Phase 1
Overweight or Obese Participants

Active registered Phase 1–3 trials from ClinicalTrials.gov — not the company's official IR pipeline (no preclinical or undisclosed assets). Grouped by trial intervention name; therapeutic area is auto-categorized. Each indication links to its trial. Molecular targets sourced from ChEMBL (EMBL-EBI).

Targets from a ChEMBL (EMBL-EBI) snapshot dated 2026-08-20 · 310/1701 assets resolved when it was built

See the full biopharma catalyst calendar across all covered companies.